FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Tapper Amy E.		 2. Issuer Name and Ticker or Trading Symbol

Imago BioSciences, Inc. [ IMGO ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
See Remarks
(Last)          (First)          (Middle)

C/O IMAGO BIOSCIENCES, INC., 303 TWIN DOLPHIN DRIVE, 6TH FLOOR		 3. Date of Earliest Transaction (MM/DD/YYYY)

1/3/2023
(Street)

REDWOOD CITY, CA 94065
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/3/2023  M  7482 A$2.52 127315 (1)D  
Common Stock 1/3/2023  M  12400 A$4.2 139715 D  
Common Stock 1/3/2023  M  1379 A$22.76 141094 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy) $2.52 1/3/2023  M     7482  1/1/2021 3/28/2027 Common Stock 7482 $0 750 D  
Stock Option (Right to Buy) $4.2 1/3/2023  M     12400   (2)2/4/2031 Common Stock 12400 $0 11409 D  
Stock Option (Right to Buy) $22.76 1/3/2023  M     1379   (3)11/16/2031 Common Stock 1379 $0 90121 D  
Explanation of Responses:
(1) Reflects the adjusted total which includes the purchase of 786 shares under the Imago Employee Stock Purchase Plan on November 30, 2022.
(2) One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from November 12, 2020 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
(3) 25% of the shares subject to the option vest on the first anniversary measured from November 17, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Tapper Amy E.
C/O IMAGO BIOSCIENCES, INC.
303 TWIN DOLPHIN DRIVE, 6TH FLOOR
REDWOOD CITY, CA 94065

See Remarks
Signatures
/s/ Hugh Rienhoff, as Attorney-in-Fact for Amy E. Tapper1/5/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Imago BioSciences (NASDAQ:IMGO)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Imago BioSciences Charts.
Imago BioSciences (NASDAQ:IMGO)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Imago BioSciences Charts.